Bibliography
- Prusiner SB : Prions.Proc. Natl Acad. Sci. USA95, 13363–13383 (1998).
- Cunningham C , DeaconR, WellsHet al.: Synaptic changes characterize early behavioural signs in the ME7 model of murine prion disease. Eur. J. Neurosci.17, 2147–2155 (2003).
- Bate C , TayebiM, WilliamsA: Sequestration of free cholesterol in cell membranes by prions correlates with cytoplasmic phospholipase A2 activation.BMC Biol.6, 8 (2008).
- Chang T -Y, Chang CCY, Ohgami N, Yamauchi Y: Cholesterol sensing, trafficking, and esterification. Annu. Rev. Cell Dev. Biol.22, 129–157 (2006).
- Schroeder F , GallegosAM, AtshavesMPet al.: Recent advances in membrane microdomains: rafts, caveolae, and intracellular cholesterol trafficking. Exp. Biol. Med226, 873–890 (2001).
- Stahl N , BaldwinMA, HeckerR, PanKM, BurlingameAL, PrusinerSB: Glycosylinositol phospholipid anchors of the scrapie and cellular prion proteins contain sialic acid.Biochemistry31, 5043–5053 (1992).
- Pike LJ : Lipid rafts: heterogeneity on the high seas.Biochem. J.378, 281–292 (2004).
- Vey M , PilkuhnS, WilleHet al.: Subcellular colocalization of the cellular and scrapie prion proteins in caveolae-like membranous domains. Proc. Natl Acad. Sci. USA93, 14945–14949 (1996).
- Massimino ML , GriffoniC, SpisniE, ToniM, TomasiV: Involvement of caveolae and caveolae-like domains in signalling, cell survival and angiogenesis.Cell. Signal.14, 93–98 (2002).
- Schmitt-Ulms G , LegnameG, BaldwinMAet al.: Binding of neural cell adhesion molecules (N-CAMs) to the cellular prion protein. J. Mol. Biol.314, 1209–1225 (2001).
- Tsui-Pierchala BA , EncinasM, MilbrandtJ, JohnsonEM: Lipid rafts in neuronal signaling and function.Trends Neurosci.25, 412–417 (2002).
- Farooqui AA , Ong W-Y, Horrocks LA: Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Phamacol. Rev.58, 591–620 (2006).
- Bate C , ReidS, WilliamsA: Phospholipase A2 inhibitors or platelet activating factor antagonists prevent prion replication.J. Biol. Chem.279, 36405–36411 (2004).
- Bate C , SalmonaM, DiomedeL, WilliamsA: Squalestatin cures prion-infected neurones and protects against prion neurotoxicity.J. Biol. Chem.279, 14983–14990 (2004).
- Bate C , TayebiM, WilliamsA: Cholesterol esterification reduces the neurotoxicity of prions.Neuropharmacology DOI: 10.1016/j.neuropharm.2008.04.002 (2008) (Epub ahead of print).
- Li S , CouetJ, LisantiML: Src tyrosine kinases, Gα Subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases.J. Biol. Chem.271, 29182–29190 (1996).
- Cooper DMF , CrossthwaiteAJ: Higher-order organization and regulation of adenylyl cyclases.Trends Pharmacol. Sci.27, 426–431 (2006).
- Oh P , SchnitzerJE: Segregation of heterotrimeric G proteins in cell surface microdomains. Gq binds caveolin to concentrate in caveolae, whereas Gi and Gs target lipid rafts by default.Mol. Biol. Cell12, 685–698 (2001).
- Sathishkumar K , MurthySN, UppuRM: Cytotoxic effects of oxysterols produced during ozonolysis of cholesterol in murine GT1–7 hypothalamic neurons.Free Radic. Res.41, 82–88 (2007).
- Mann RK , BeachyPA: Cholesterol modification of proteins.Biochim. Biophys. Acta1529, 188–202 (2000).
- Maxfield FR , TabasI: Role of cholesterol and lipid organization in disease.Nature438, 612–21 (2005).
- Allen JA , Halverson-TamboliRA, Rasenick MM: Lipid raft microdomains and neurotransmitter signalling. Nat. Rev. Neurosci.8, 128–140 (2007).
- Goritz C , MauchDH, PfriegerFW: Multiple mechanisms mediate cholesterol-induced synaptogenesis in a CNS neuron.Mol. Cell. Neurosci.29, 190–201 (2005).
- Sandberg MK , LowP: Altered interaction and expression of proteins involved in neurosecretion in scrapie-infected GT1-1 cells.J. Biol. Chem.280, 1264–1271 (2005).
- Ferrer I : Synaptic pathology and cell death in the cerebellum in Creutzfeldt–Jakob disease.Cerebellum1, 213–222 (2002).
- Rottkamp CA , AtwoodCS, JosephJA, NunomuraA, PerryG, SmithMA: The state versus amyloid-β: the trial of the most wanted criminal in Alzheimer disease.Peptides23, 1333–1341 (2002).
- Lee VMY , TrojanowskiJQ: Mechanisms of Parkinson‘s disease linked to pathological α-synuclein: new targets for drug discovery.Neuron52, 33–38 (2006).
- Li G , LarsonEB, SonnenJAet al.: Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology69, 878–885 (2007).
- Wolozin B , WangS, Li N-C, Lee A, Lee T, Kazis L: Simvastatin is associated with a reduced incidence of dementia and Parkinson‘s disease. BMC Med.5, 20 (2007).
- Neuhaus O , StuveO, ZamvilSS, Hartung HP: Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles. CNS Drugs19, 833–841 (2005).